Biotechnology major Biocon’s subsidiary Biocon Biologics and partner Mylan have launched insulin glargine injection, under the brand name Semglee, in the US market, said the Bengaluru-based company on Monday.
Biocon Biologics India and Mylan have launched the product in vial and pre-filled pen presentations in the US, Biocon said. It is approved to help control high blood sugar in adult and pediatric patients with type-1 diabetes and adults with type-2 diabetes. Mylan, which is responsible for commercialisation in the US, would offer Semglee at a wholesale cost of $147.98 per package of five 3ml pens and $98.65 per 10ml vial, making